Dwyer Bonnie K, Krieg Sacha, Balise Raymond, Carroll Ian R, Chueh Jane, Nayak Nihar, Druzin Maurice
Department of Obstetrics and Gynecology, Santa Clara Valley Medical Center, 751 S. Bascom Ave., San Jose, CA 95128, USA.
J Matern Fetal Neonatal Med. 2010 Jul;23(7):705-11. doi: 10.3109/14767050903258753.
To explore angiogenic factor differences in preeclamptic patients according to the absence or presence of underlying vascular disease.
We prospectively compared serum soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin, and placental growth factor (PlGF) from 41 normal-risk and 32 high-risk (preexisting conditions) subjects at serial gestational ages.
Median sFlt1 was lower at delivery in preeclamptic patients with underlying chronic hypertension and/or chronic proteinuria (5115 pg/ml) compared with normal risk preeclamptic patients (16375 pg/ml). PlGF was consistently low in patients who developed preeclampsia.
Effects of sFlt1 may be contextual, varying according to the health or disease state of vascular endothelium.
根据是否存在潜在血管疾病，探讨子痫前期患者血管生成因子的差异。
我们前瞻性地比较了41名正常风险和32名高风险（存在基础疾病）受试者在不同孕周时血清可溶性fms样酪氨酸激酶1（sFlt1）、可溶性内皮糖蛋白和胎盘生长因子（PlGF）的水平。
与正常风险子痫前期患者（16375 pg/ml）相比，患有慢性高血压和/或慢性蛋白尿的子痫前期患者分娩时sFlt1中位数较低（5115 pg/ml）。发生子痫前期的患者PlGF水平持续较低。
sFlt1的作用可能因情况而异，随血管内皮的健康或疾病状态而变化。
